Search Results

Return to List
Results 1–20 of 37
Title Date
1.

Access to Emergency Contraception

Number 542

ABSTRACT: Emergency contraception includes contraceptive methods used to prevent pregnancy in the first few days after unprotected intercourse, sexual assault, or contraceptive failure. Although the ...

November 2012

PDF Format
2.

Analgesia and Cesarean Delivery Rates

Number 339

(Reaffirmed 2013, Replaces No. 269, February 2002)

ABSTRACT: Neuraxial analgesia techniques are the most effective and least depressant treatments for labor pain. The American College of Obstetricians and Gynecologists previously recommended that pra...

June 2006

PDF Format
3.

Aromatase Inhibitors in Gynecologic Practice

Number 412

(Reaffirmed 2012)

ABSTRACT: Aromatase inhibitors appear to be effective as an adjuvant treatment for early-stage and late-stage breast cancer. Their role in chemoprevention of breast cancer in high-risk patients remai...

August 2008

PDF Format
4.

Brand Versus Generic Oral Contraceptives

Number 375

(Reaffirmed 2013)

ABSTRACT:The U.S. Food and Drug Administration considers generic and brand name oral contraceptive (OC) products clinically equivalent and interchangeable. The American College of Obstetricians and G...

August 2007

PDF Format
5.

Compounded Bioidentical Menopausal Hormone Therapy

Number 532

(Reaffirmed 2014, Replaces No. 387, November 2007 and No. 322, November 2005)

ABSTRACT: Although improvement in long-term health is no longer an indication for menopausal hormone therapy, evidence supporting fewer adverse events in younger women, combined with its high overall...

August 2012

PDF Format
6.

Emergent Therapy for Acute-Onset Severe Hypertension with Preeclampsia and Eclampsia

Number 514

ABSTRACT: Acute-onset, persistent (lasting 15 minutes or more), severe systolic (greater than or equal to 160 mm Hg) or severe diastolic hypertension (greater than or equal to 110 mm Hg) or both in p...

December 2011

PDF Format
7.

Ethical Issues in Pandemic Influenza Planning Concerning Pregnant Women

Number 563

ABSTRACT: Pregnant women traditionally have been assigned priority in the allocation of prevention and treatment resources during outbreaks of influenza because of their increased risk of morbidity a...

May 2013

PDF Format
8.

Ethical Issues With Vaccination for the Obstetrician–Gynecologist

Number 564

ABSTRACT: Because of the growing importance of infectious disease prevention in the individual patient and the larger community, it is vital that Fellows of the American College of Obstetricians and ...

May 2013

PDF Format
9.

Improving Medication Safety

Number 531

(Replaces No. 331, April 2006 and No. 400, March 2008)

ABSTRACT: Despite significant national attention, medical errors continue to pervade the U.S. health care system. Medication-related errors consistently rank at the top of all medical errors, which a...

August 2012

PDF Format
10.

Influenza Vaccination During Pregnancy

Number 468

(Replaces No. 305, November 2004)

ABSTRACT: Preventing influenza during pregnancy is an essential element of prenatal care, and the most effective strategy for preventing influenza is annual immunization. The Centers for Disease Cont...

October 2010

PDF Format
11.

Integrating Immunizations Into Practice

Number 558

ABSTRACT: Given demonstrated vaccine efficacy, safety, and the large potential for prevention of many infectious diseases among adults, newborns, and pregnant women, obstetrician–gynecologists should...

April 2013

PDF Format
12.

Labor Induction or Augmentation and Autism

Number 597

Abstract: Functional oxytocin deficiency and a faulty oxytocin signaling pathway have been observed in conjunction with autism spectrum disorder (ASD). Because exogenous synthetic oxytocin commonly i...

May 2014

PDF Format
13.

Magnesium Sulfate Before Anticipated Preterm Birth for Neuroprotection

Number 455

(Reaffirmed 2013)

ABSTRACT: Numerous large clinical studies have evaluated the evidence regarding magnesium sulfate, neuroprotection, and preterm births. The Committee on Obstetric Practice and the Society for Materna...

March 2010

PDF Format
14.

Magnesium Sulfate Use in Obstetrics

Number 573

ABSTRACT: The U.S. Food and Drug Administration advises against the use of magnesium sulfate injections for more than 5–7 days to stop preterm labor in pregnant women. Based on this, the drug classif...

September 2013

PDF Format
15.

Management of Acute Abnormal Uterine Bleeding in Nonpregnant Reproductive-Aged Women

Number 557

ABSTRACT: Initial evaluation of the patient with acute abnormal uterine bleeding should include a prompt assessment for signs of hypovolemia and potential hemodynamic instability. After initial asses...

April 2013

PDF Format
16.

Misoprostol for Postabortion Care

Number 427

ABSTRACT: The World Health Organization estimates that 67,000 women, mostly in developing countries, die each year from untreated or inadequately treated abortion complications. Postabortion care, a ...

February 2009

PDF Format
17.

Nalbuphine Hydrochloride Use for Intrapartum Analgesia

Number 376

(Reaffirmed 2012)

ABSTRACT: Safety concerns have been raised regarding the use of nalbuphine hydrochloride during labor. The American College of Obstetricians and Gynecologists finds data are insufficient to recommend...

August 2007

PDF Format
18.

Nonmedical Use of Prescription Drugs

Number 538

(Reaffirmed 2014)

ABSTRACT: The nonmedical use of prescription drugs, particularly opioids, sedatives, and stimulants, has been cited as epidemic in the United States, accounting for increasing numbers of emergency de...

October 2012

PDF Format
19.

Nonobstetric Surgery During Pregnancy

Number 474

(Reaffirmed 2013, Replaces No. 284, August 2003)

ABSTRACT: The American College of Obstetricians and Gynecologists' Committee on Obstetric Practice acknowledges that the issue of nonobstetric surgery during pregnancy is an important concern for phy...

February 2011

PDF Format
20.

OnabotulinumtoxinA and the Bladder

Number 604

ABSTRACT: In January 2013, the U.S. Food and Drug Administration approved the use of onabotulinumtoxinA (also known as Botox A) for the treatment of overactive bladder, thus providing another treatme...

June 2014

PDF Format